Drugs / ASP1617
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04077879 | Sep 2019 → Jun 2021 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP1617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04077879 ↗ |
| Action | Inhibit | “ASP1617 is a novel, highly selective inhibitor of cathepsin-S” PMID 41577633 ↗ Feb 2026 |
| Route | Oral | “Oral” NCT04077879 ↗ |